260 related articles for article (PubMed ID: 33506674)
21. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
22. ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
Xu SH; Zhu S; Wang Y; Huang JZ; Chen M; Wu QX; He YT; Chen D; Yan GR
Cell Death Dis; 2018 May; 9(5):479. PubMed ID: 29706618
[TBL] [Abstract][Full Text] [Related]
23. The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization.
Tang DE; Dai Y; Xu Y; Lin LW; Liu DZ; Hong XP; Ou ML; Jiang HW; Xu SH
Carcinogenesis; 2020 Mar; 41(1):56-66. PubMed ID: 31046116
[TBL] [Abstract][Full Text] [Related]
24. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
Guha P; Gardell J; Darpolor J; Cunetta M; Lima M; Miller G; Espat NJ; Junghans RP; Katz SC
Oncogene; 2019 Jan; 38(4):533-548. PubMed ID: 30158673
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and activity of BBI608 derivatives targeting on stem cells.
Zhou Q; Peng C; Du F; Zhou L; Shi Y; Du Y; Liu D; Sun W; Zhang M; Chen G
Eur J Med Chem; 2018 May; 151():39-50. PubMed ID: 29604543
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
[TBL] [Abstract][Full Text] [Related]
27. A perylene derivative regulates HIF-1α and Stat3 signaling pathways.
Chen H; Guan Y; Yuan G; Zhang Q; Jing N
Bioorg Med Chem; 2014 Feb; 22(4):1496-505. PubMed ID: 24485121
[TBL] [Abstract][Full Text] [Related]
28. ZFP91 promotes cell proliferation and inhibits cell apoptosis in AML via inhibiting the proteasome-dependent degradation of RIP1.
Zhang Z; Zhong L; Dan W; Chu X; Liu C; Luo X; Wan P; Liu Z; Lu Y; Wang X; Liu B
Int J Med Sci; 2022; 19(2):274-285. PubMed ID: 35165513
[TBL] [Abstract][Full Text] [Related]
29. E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation.
Lochab S; Pal P; Kapoor I; Kanaujiya JK; Sanyal S; Behre G; Trivedi AK
Biochim Biophys Acta; 2013 Dec; 1833(12):2639-2652. PubMed ID: 23820376
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
Xu XL; Yang YR; Mo XF; Wei JL; Zhang XJ; You QD
Eur J Med Chem; 2017 Sep; 137():45-62. PubMed ID: 28554092
[TBL] [Abstract][Full Text] [Related]
32. E6AP inhibits G-CSFR turnover and functions by promoting its ubiquitin-dependent proteasome degradation.
Chhabra S; Kumar Y; Thacker G; Kapoor I; Lochab S; Sanyal S; Bhatt MLB; Chattopadhyay N; Trivedi AK
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1545-1553. PubMed ID: 28578910
[TBL] [Abstract][Full Text] [Related]
33. Putative E3 ubiquitin ligase of human rotavirus inhibits NF-κB activation by using molecular mimicry to target β-TrCP.
Morelli M; Dennis AF; Patton JT
mBio; 2015 Jan; 6(1):. PubMed ID: 25626907
[TBL] [Abstract][Full Text] [Related]
34. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3.
Xing Y; Mi C; Wang Z; Zhang ZH; Li MY; Zuo HX; Wang JY; Jin X; Ma J
Pharmacol Res; 2018 Sep; 135():166-180. PubMed ID: 30103001
[TBL] [Abstract][Full Text] [Related]
35. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
[TBL] [Abstract][Full Text] [Related]
36. 1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
Eur J Med Chem; 2017 Nov; 140():84-91. PubMed ID: 28923389
[TBL] [Abstract][Full Text] [Related]
37. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
38. FBXO11 represses cellular response to hypoxia by destabilizing hypoxia-inducible factor-1α mRNA.
Ju UI; Park JW; Park HS; Kim SJ; Chun YS
Biochem Biophys Res Commun; 2015 Sep; 464(4):1008-1015. PubMed ID: 26187670
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
[TBL] [Abstract][Full Text] [Related]
40. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
